查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878898

腫瘤生物相似藥市場－全球產業規模、佔有率、趨勢、機會及預測，依藥物類別、癌症類型、配銷通路、地區及競爭格局分類，2020-2030年預測

Oncology Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Type of Cancer, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球腫瘤生物相似藥市場規模為45.4億美元，預計2030年將以6.94%的複合年成長率成長至67.9億美元。腫瘤生物相似藥是指與已核准的原廠腫瘤生物製品高度相似的生物製品，在安全性、純度和效力方面均無臨床意義上的差異。該市場擴張的根本驅動力在於全球各類癌症發生率的不斷上升以及眾多重磅腫瘤生物製劑專利即將到期，這為低成本替代藥物的開發創造了機會。

市場概覽
預測期 2026-2030
2024年市場規模 45.4億美元
2030年市場規模 67.9億美元
2025-2030年複合年成長率 6.94%
成長最快的細分市場 肺癌
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球腫瘤生物相似藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（單株抗體、粒細胞集落刺激因子、造血因子、其他）
    • 依癌症類型分類（乳癌、肺癌、胃癌、攝護腺癌、子宮頸癌、血癌、腦癌、其他）
    • 按配銷通路（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美腫瘤生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腫瘤生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腫瘤生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腫瘤生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腫瘤生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球腫瘤生物相似藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Teva Pharmaceuticals Industries Ltd.
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech, Inc.
  • Sandoz Group AG
  • Samsung Bioepis NL BV
  • Pfizer Inc.
  • Ligand Pharmaceuticals Inc.
  • Mylan Inc.
  • Innovent Biologics (USA), Inc.
  • Celltrion Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 17259

The Global Oncology Biosimilars Market, valued at USD 4.54 Billion in 2024, is projected to experience a CAGR of 6.94% to reach USD 6.79 Billion by 2030. Oncology biosimilars are biological products demonstrably highly similar to an approved original oncology biological product, exhibiting no clinically meaningful differences regarding safety, purity, and potency. The market's expansion is fundamentally driven by the increasing global incidence of various cancer types and the impending patent expiration of numerous blockbuster oncology biologics, which creates opportunities for lower-cost alternatives.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.54 Billion
Market Size 2030USD 6.79 Billion
CAGR 2025-20306.94%
Fastest Growing SegmentLung Cancer
Largest MarketNorth America

Key Market Drivers

The increasing global incidence of cancer serves as a primary catalyst for the oncology biosimilars market, generating substantial demand for effective yet affordable treatment solutions. As the worldwide cancer burden rises, healthcare systems are compelled to seek cost-efficient therapeutic alternatives to manage growing patient populations and control expenditures. This rising prevalence directly drives the necessity for accessible oncology therapies, with biosimilars playing a pivotal role in expanding treatment access.

Key Market Challenges

A significant challenge impeding the broader expansion of the Global Oncology Biosimilars Market is the substantial investment and intricate scientific expertise required for biosimilar development and manufacturing processes, alongside the necessity for extensive regulatory validation. This inherent complexity and considerable financial outlay directly deter potential manufacturers and prolong the market entry of oncology biosimilar products. The development pathway demands rigorous analytical characterization, preclinical evaluation, and clinical trials to establish biosimilarity to the original biologic, which is both capital-intensive and time-consuming.

This challenging development environment limits the number of pharmaceutical companies capable of undertaking such programs, especially for complex oncology biologics. Consequently, many reference products, even after patent expiration, do not face biosimilar competition.

Key Market Trends

The growing acceptance and trust in clinical settings significantly influences the global oncology biosimilars market by fostering greater confidence among healthcare professionals and patients. This increased assurance directly translates into higher adoption rates for biosimilar treatments. According to the Association for Accessible Medicines, biosimilar medicines generated $20.2 billion in savings in 2024 alone, highlighting their crucial economic value which underpins broader acceptance. Furthermore, a survey conducted on behalf of the Alliance for Safe Biologic Medicines in August 2024, revealed that 88% of physicians agree switching studies enhance their confidence in the safety of transitioning patients from an originator medicine to an interchangeable biosimilar. This robust physician confidence is paramount for overcoming historical skepticism and driving market penetration.

Key Market Players

  • Teva Pharmaceuticals Industries Ltd.
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech, Inc.
  • Sandoz Group AG
  • Samsung Bioepis NL B.V.
  • Pfizer Inc.
  • Ligand Pharmaceuticals Inc.
  • Mylan Inc.
  • Innovent Biologics (USA), Inc.
  • Celltrion Inc.

Report Scope:

In this report, the Global Oncology Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Biosimilars Market, By Drug Class:

  • Monoclonal Antibodies
  • G-CSF
  • Hematopoietic Agents
  • Others

Oncology Biosimilars Market, By Type of Cancer:

  • Breast Cancer
  • Lung Cancer
  • Stomach Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Blood Cancer
  • Brain Cancer
  • Others

Oncology Biosimilars Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Oncology Biosimilars Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oncology Biosimilars Market.

Available Customizations:

Global Oncology Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Biosimilars Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
    • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
    • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Oncology Biosimilars Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type of Cancer
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oncology Biosimilars Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type of Cancer
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Oncology Biosimilars Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type of Cancer
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Oncology Biosimilars Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type of Cancer
        • 6.3.3.2.3. By Distribution Channel

7. Europe Oncology Biosimilars Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type of Cancer
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oncology Biosimilars Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type of Cancer
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Oncology Biosimilars Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type of Cancer
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Oncology Biosimilars Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type of Cancer
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Oncology Biosimilars Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type of Cancer
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Oncology Biosimilars Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type of Cancer
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oncology Biosimilars Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type of Cancer
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oncology Biosimilars Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type of Cancer
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Oncology Biosimilars Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type of Cancer
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Oncology Biosimilars Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type of Cancer
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Oncology Biosimilars Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type of Cancer
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Oncology Biosimilars Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type of Cancer
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Oncology Biosimilars Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type of Cancer
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oncology Biosimilars Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type of Cancer
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Oncology Biosimilars Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type of Cancer
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Oncology Biosimilars Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type of Cancer
        • 9.3.3.2.3. By Distribution Channel

10. South America Oncology Biosimilars Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type of Cancer
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oncology Biosimilars Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type of Cancer
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Oncology Biosimilars Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type of Cancer
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Oncology Biosimilars Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type of Cancer
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oncology Biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceuticals Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. STADA Arzneimittel AG
  • 15.3. Shanghai Henlius Biotech, Inc.
  • 15.4. Sandoz Group AG
  • 15.5. Samsung Bioepis NL B.V.
  • 15.6. Pfizer Inc.
  • 15.7. Ligand Pharmaceuticals Inc.
  • 15.8. Mylan Inc.
  • 15.9. Innovent Biologics (USA), Inc.
  • 15.10. Celltrion Inc.

16. Strategic Recommendations

17. About Us & Disclaimer